A Phase 3 interventional study of Rusfertide and Placebo in Polycythemia Vera, sponsored by Protagonist Therapeutics, Inc.. Active, not recruiting at 184 sites in 20 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-19.
Sponsored by Protagonist Therapeutics, Inc. · Phase 3, Interventional, and Treatment
…and 4 more changes, on the record history on ClinicalTrials.gov ↗
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 179 studies in Polycythemia Vera with a site in United States — 22 open to participants now, 34 under way, 7 of them phase 3. Polycythemia Vera · United States.
Among the 179 studies in Polycythemia Vera with a site in United States, this one is the 8th largest by enrollment of the 150 interventional ones that give a count, is one of 4 that started in 2022, is one of 18 in phase 3, reaches primary completion later than 3 of the 33 other live ones, and was the 157th registered.
278 studies on the registry are indexed under Polycythemia Vera; 53 are open to participants now.
Browse Polycythemia Vera studies →22 of the 179 studies in Polycythemia Vera with a site in United States are open now. Recruiting first, the newest first:
Memorial Sloan Kettering Cancer Center · Sites in United States
Ages 18+
Merck Sharp & Dohme LLC · Sites in United States, Canada, Israel
Ages 18+
Massachusetts General Hospital · Sites in United States
Healthy volunteers
Ono Pharmaceutical Co., Ltd. · Sites in United States, Australia, Austria and 6 more countries
Ages 18+
Incyte Corporation · Sites in United States, Australia, Belgium and 8 more countries
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 42 Polycythemia Vera studies recruiting now, 38 (90%) set no upper age limit and 1 (2%) stops at 75 or younger; 4 take children under 18; 1 takes healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
179 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 61 · Phase 2 89 · Phase 3 20
First in 1992; this study’s year is marked. 4 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 293 is above the median of 52 across 204 interventional studies indexed under Polycythemia Vera.
Median enrollment 40 across the 150 interventional studies, 678 across the 15 observational. Of the 135 that completed or were terminated, 54 (40%) have results posted.
This tab as a report to print or save as PDF → With an account.
43 of 179 have an industry lead sponsor. The 10 most frequent:
Protagonist Therapeutics, Inc. is the lead sponsor of 13 studies on the registry; none are open to participants now.
Of its 9 completed or terminated interventional studies of FDA-regulated products, 1 (11%) have results posted.
Protagonist Therapeutics, Inc. has 4 studies filed under Polycythemia Vera — fewer than ten, so there is no comparison to draw.
9 of the studies in Polycythemia Vera with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT04041050AbbVieA Study Evaluating Safety and Tolerability, and Pharmacokinetics of Navitoclax Monotherapy and in Combination With Ruxolitinib in Participants With Myeloproliferative Neoplasm | 2026-12-31 |
| NCT07203768FROM- Fondazione per la Ricerca Ospedale di Bergamo- ETSA ELN-Multicenter Study on Phenotypic Evolution and Clinical Outcomes | 2026-12-31 |
| NCT06063486University of Southern CaliforniaCurcumin to Improve Inflammation and Symptoms in Patients With Clonal Cytopenia of Undetermined Significance, Low Risk Myelodysplastic Syndrome, and Myeloproliferative Neoplasms | 2026-12-31 |
| NCT05714072Memorial Sloan Kettering Cancer CenterA Study of Ruxolitinib in Combination With Abemaciclib for the Treatment of Myelofibrosis | 2027-01 |
| NCT03862157M.D. Anderson Cancer CenterAzacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia | 2027-01-31 |
Add all 9 to your calendar (.ics) → With an account.
Among the 179 studies in Polycythemia Vera with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Polycythemia vera (PV) is a long-term condition in which the bone marrow makes too many red blood cells (RBCs). Bone marrow is the soft tissue inside the large bones where blood cells are made. When there are too many RBCs, called erythrocytosis, the blood can become thicker and move less easily through blood vessels and organs. This can raise the risk of blood clots (thrombosis) in veins or arteries. Sometimes, these clots can be life-threatening and may cause a stroke or heart attack. Treatment aims to keep the percentage of RBCs in the blood (hematocrit) in a safe range. For adults with PV, this means keeping the hematocrit below 45%. This helps lower the blood thickness and the risk of thrombosis. PV can also be linked to low iron levels (iron deficiency), because the body uses iron to make more RBCs. Many people with PV are treated with blood removal (phlebotomy) to lower RBC levels in the blood. This can worsen the iron deficiency, because each blood removal also takes iron out of the body.
Rusfertide is a medicine that lowers the amount of iron available in the blood. It works like hepcidin, a natural hormone that helps control iron levels in the body. By limiting iron available for RBC production, rusfertide may help keep hematocrit below 45% and may improve symptoms. It may also reduce, or even remove, the need for phlebotomy in people.
The main aim of this study is to check how well rusfertide works compared with placebo to lower the number of phlebotomies. A placebo looks like rusfertide but does not have any medicine in it.
Other aims are to learn how safe rusfertide is compared with placebo and to understand how well it works to reduce the need for phlebotomy and to keep hematocrit levels under control. The study also wants to learn how rusfertide moves through the body (pharmacokinetics) and how it affects the body (pharmacodynamics or PD).
This study has 4 parts that follow each other:
During the study, participants will visit the study clinical several times at fixed timepoints.
The criteria were revised on the registry on Oct 19, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Phlebotomy requiring defined as ALL of the following:
Complete blood count (CBC) values immediately prior to randomization:
Participants receiving cytoreductive therapy at randomization must be on a stable PV therapy regimen as follows:
Participants treated with phlebotomy alone at randomization must have stopped:
Exclusion criteria:
laboratory abnormalities at Screening, including but not limited to the following:
History of invasive within the last 5 years, except
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received their ongoing therapy for polycythemia vera (PV) along with rusfertide-matching placebo, subcutaneous (SC) injection, once weekly, from baseline up to Week 32.
Drug: Placebo
Participants received their ongoing therapy for PV along with rusfertide once weekly, SC injection, from baseline up to Week 32. Rusfertide doses were titrated to maintain hematocrit less than (\<) 45 percent (%). The starting dose was 19 milligrams (mg). The doses that were administered to Part 1a participants were 9.5, 19, 28, 41, 54, 69 and 82 mg.
Drug: Rusfertide
Participants received rusfertide once weekly, SC injection, from Weeks 32 to 52. Rusfertide doses were titrated to maintain hematocrit \< 45%. Participants who received rusfertide in Part 1a continued at their current dose unless dose adjustment was required. Participants who received placebo in Part 1a started rusfertide at 19 mg. The doses that were administered to Part 1b participants were 9.5, 19, 28, 41, 54, 69 and 82 mg.
Drug: Rusfertide
Participants received rusfertide once weekly, SC injection, from Weeks 52 to 156. Rusfertide doses were titrated to maintain hematocrit \< 45%. The doses that were administered to Part 2 participants were 9.5, 19, 28, 41, 54, 69, 82, 95 and 108 mg. For weekly doses greater than (\>) 90 mg, the dose of rusfertide was and will be divided into 2 doses administered 3 to 4 days apart.
Drug: Rusfertide
Participants will receive rusfertide once weekly, SC injection, from Week 156 to the end of the study (approximately 5 years). Rusfertide doses will be titrated to maintain hematocrit \< 45%. The doses that will be administered to Part 3 participants are 9.5, 19, 28, 41, 54, 69, 82, 95 and 108 mg. For weekly doses \> 90 mg, the dose of rusfertide will be divided into 2 doses administered 3 to 4 days apart.
Drug: Rusfertide
Rusfertide SC injection
Rusfertide-matching placebo SC injection
Part 1a: Percentage of Participants Who Achieved Response
Response was defined as absence of phlebotomy eligibility. Phlebotomy eligibility was defined as either: 1) A confirmed hematocrit (HCT) greater than or equal to (≥) 45% that was at least 3% higher than the baseline HCT, where confirmation was defined as 2 consecutive HCT assessments that were ≥ 45% and at least 3% higher than the baseline HCT, or 2) HCT ≥ 48%.
Time frame: From Weeks 20 to 32
Part 1a: Number of Phlebotomies
Time frame: Baseline to Week 32
Part 1a: Percentage of Participants With All Hematocrit Values < 45%
Time frame: Baseline to Week 32
Part 1a: Change From Baseline in the Patient Reported Outcomes Measurement Information System (PROMIS) Fatigue Short Form 8a Total T-score
The PROMIS Fatigue SF 8a T-score will be obtained via the item-response theory (IRT) response-pattern scoring approach using the PROMIS Scoring Service available at https://www.assessmentcenter.net/ac\_scoringservice. It is an National Institutes of Health (NIH)-developed fatigue survey of 8 items that asks the participant about fatigue experience and impact over the past 7 days. Each item will be scored on a 5-point Likert scale (1=never/not at all to 5=almost always/very much). Raw scores (range: 8-40) will be converted into standardized T scores (range: 34.1-80.9), with higher scores indicating greater fatigue severity. A negative change from baseline indicates an improvement.
Time frame: Baseline, Week 32
Part 1a: Change From Baseline in the Myelofibrosis Symptom Assessment Form (MFSAF) Version 4.0 Total Symptom Score-7 (TSS7) Items
The MFSAF version 4.0 (v4.0) TSS7 is a questionnaire developed by the Patient-Reported Outcome (PRO) Consortium's Myelofibrosis Working Group that focuses on the 7 core symptoms of myelofibrosis: fatigue, night sweats, pruritus, abdominal discomfort, pain under the ribs on the left side, early satiety, and bone pain. It includes 7 items on a 0 (absent) to 10 (worst imaginable) numeric rating scale. A higher score indicates worse symptoms. A negative change from baseline indicates an improvement.
Time frame: Baseline, Week 32
Part 1a: Change From Baseline in the PROMIS Fatigue Short Form 8a Total T-score Among Participants Who Have Moderate or Severe Symptoms at Baseline
The PROMIS Fatigue SF 8a T-score will be obtained via the IRT response-pattern scoring approach using the PROMIS Scoring Service available at https://www.assessmentcenter.net/ac\_scoringservice. It is a National Institutes of Health (NIH)-developed fatigue survey of 8 items that asks the participant about fatigue experience and impact over the past 7 days. Each item will be scored on a 5-point Likert scale (1=never/not at all to 5=almost always/very much). Raw scores (range: 8-40) will be converted into standardized T scores (range: 34.1-80.9), with higher scores indicating greater fatigue severity. Moderate or severe symptoms are defined as a baseline PROMIS Fatigue SF 8aT-score \>/= 58.8. A negative change from baseline indicates an improvement.
Time frame: Baseline, Week 32
Part 1a: Change From Baseline in the MFSAF Total Symptom Score-4 Items (TSS4) Among Participants Who Have Moderate or Severe Symptoms at Baseline
The MFSAF v4.0 is a questionnaire developed by the PRO Consortium's Myelofibrosis Working Group that focused on the 7 core symptoms of myelofibrosis: fatigue, night sweats, pruritus, abdominal discomfort, pain under the ribs on the left side, early satiety, and bone pain. Items are scored on a 0 (absent) to 10 (worst imaginable) numeric rating scale. The MFSAF TSS4 is the sum of four items in the MFSAF (fatigue, itching \[pruritis\], night sweats, and abdominal discomfort). The weekly TSS4 will be calculated by averaging daily scores over a 7-day interval leading to Week 32 (inclusive). Moderate or severe symptoms are defined as a baseline MFSAF TSS4 \>/=9.1. A higher score indicates worse symptoms. A negative change from baseline indicates an improvement.
Time frame: Baseline, Week 32
Part 1a: Change From Baseline in the Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF) Problems With Concentration Among Participants Who Have Moderate or Severe Symptoms at Baseline
MPN-SAF is a 10-item questionnaire measurement tool for symptoms of MPNs. Moderate or severe symptoms are defined as baseline MPN-SAF problems with concentration ≥4. The descriptive analysis approach the distribution of the MPN-SAF problems with concentration at Baseline will be categorized using the Patient Global Impression of Severity (PGI-S). The response quartiles will be used to establish the recommended cut-off points for the MPN-SAF Problems with Concentration corresponding to "none" or "mild" versus "moderate or "severe" categories on the PGI-S.
Time frame: Baseline, Week 32
Part 1a: Percentage of Participants With a Meaningful Within-person Change at Week 32 in the PROMIS Fatigue SF 8a Total T-score Among Participants Who Have Moderate or Severe Symptoms at Baseline
The PROMIS Fatigue SF 8a T-score will be obtained via the IRT response-pattern scoring approach using the PROMIS Scoring Service available at https://www.assessmentcenter.net/ac\_scoringservice. It is an NIH-developed fatigue survey of 8 items that asks the participant about fatigue experience and impact over the past 7 days. Each item will be scored on a 5-point Likert scale (1=never/not at all to 5=almost always/very much). Raw scores (range: 8-40) will be converted into standardized T scores (range: 34.1-80.9), with higher scores indicating greater fatigue severity. Moderate or severe symptoms are defined as a baseline PROMIS Fatigue SF 8aT-score \>/= 58.8.
Time frame: At Week 32
Part 1a: Percentage of Participants With a Meaningful Within-person Change at Week 32 in the MFSAF TSS4 Among Participants Who Had Moderate or Severe Symptoms at Baseline
The MFSAF v4.0 is a questionnaire developed by the PRO Consortium's Myelofibrosis Working Group that focuses on the 7 core symptoms of myelofibrosis: fatigue, night sweats, pruritus, abdominal discomfort, pain under the ribs on the left side, early satiety, and bone pain. It included 7 items on a 0 (absent) to 10 (worst imaginable) numeric rating scale. The MFSAF TSS4 is the sum of four items in the MFSAF (fatigue, itching \[pruritis\], night sweats, and abdominal discomfort). The weekly TSS4 will be calculated by averaging daily scores over a 7-day interval leading to Week 32 (inclusive). Moderate or severe symptoms are defined as a baseline MFSAF TSS4 \>/=9.1.
Time frame: At Week 32
Part 1a: Percentage of Participants With a Meaningful Within-person Change at Week 32 in the MPN-SAF Problems With Concentration Among Participants Who Had Moderate or Severe Symptoms at Baseline
MPN-SAF is a 10-item questionnaire measurement tool for symptoms of MPNs. Moderate or severe symptoms are defined as baseline MPN-SAF problems with concentration ≥4. The descriptive analysis approach the distribution of the MPN-SAF problems with concentration at Baseline was categorized using the PGI-S. The response quartiles were used to establish the recommended cut-off points for the MPN-SAF Problems with Concentration corresponding to "none" or "mild" versus "moderate or "severe" categories on the PGI-S.
Time frame: At Week 32
Change From Baseline at Each Scheduled Assessment in Individual Questions and the Total Fatigue T-score Based on PROMIS Fatigue SF 8a
The PROMIS Fatigue SF 8a T-score will be obtained via the IRT response-pattern scoring approach using the PROMIS Scoring Service available at https://www.assessmentcenter.net/ac\_scoringservice. It is an NIH-developed fatigue survey that includes 8 items that asks the participant about fatigue experience and impact over the past 7 days. Each item will be scored on a 5-point Likert scale (1=never/not at all to 5=almost always/very much). Raw scores (range: 8-40) will be converted into standardized T scores (range: 34.1-80.9), with higher scores indicating greater fatigue severity.
Time frame: Baseline to end of study (up to approximately 5 years)
Change From Baseline at Each Scheduled Assessment in Individual Questions and the Total Fatigue T-score Based on PROMIS Fatigue Short Form 8a for Among Participants With Moderate or Severe Symptoms at Baseline
The PROMIS Fatigue SF 8a T-score was obtained via the IRT response-pattern scoring approach using the PROMIS Scoring Service available at https://www.assessmentcenter.net/ac\_scoringservice. It is a National Institutes of Health (NIH)-developed fatigue survey of 8 items that asks the participant about fatigue experience and impact over the past 7 days. Each item will be scored on a 5-point Likert scale (1=never/not at all to 5=almost always/very much). Raw scores (range: 8-40) will be converted into standardized T scores (range: 34.1-80.9), with higher scores indicating greater fatigue severity. Moderate or severe symptoms are defined as a baseline PROMIS Fatigue SF 8aT-score \>/= 58.8. A negative change from baseline indicates an improvement.
Time frame: Baseline to end of study (up to approximately 5 years)
Change From Baseline at Each Scheduled Assessment in Individual Symptom Score and the Total Score Based on MFSAF v4.0 TSS4
The MFSAF v4.0 is a questionnaire developed by the PRO Consortium's Myelofibrosis Working Group that focuses on the 7 core symptoms of myelofibrosis: fatigue, night sweats, pruritus, abdominal discomfort, pain under the ribs on the left side, early satiety, and bone pain. It includes 7 items on a 0 (absent) to 10 (worst imaginable) numeric rating scale. A higher score indicates worse symptoms.
Time frame: Baseline to end of study (up to approximately 5 years)
Change From Baseline at Each Scheduled Assessment in Individual Symptom Score and the MFSAF v4.0 TSS4 Among Participants With Moderate or Severe Symptoms at Baseline
The MFSAF v4.0 is a questionnaire developed by the PRO Consortium's Myelofibrosis Working Group that focused on the 7 core symptoms of myelofibrosis: fatigue, night sweats, pruritus, abdominal discomfort, pain under the ribs on the left side, early satiety, and bone pain. Items are scored on a 0 (absent) to 10 (worst imaginable) numeric rating scale. The MFSAF TSS4 is the sum of four items in the MFSAF (fatigue, itching \[pruritis\], night sweats, and abdominal discomfort). The weekly TSS4 will be calculated by averaging daily scores over a 7-day interval leading to Week 32 (inclusive). Moderate or severe symptoms are defined as a baseline MFSAF TSS4 \>/=9.1. A higher score indicates worse symptoms. A negative change from baseline indicates an improvement.
Time frame: Baseline to end of study (up to approximately 5 years)
Part 1a: Percentage of Participants With a Meaningful Within-person Change at Week 32 in the PROMIS Fatigue SF 8a Total T-score
The PROMIS Fatigue SF 8a T-score will be obtained via the IRT response-pattern scoring approach using the PROMIS Scoring Service available at https://www.assessmentcenter.net/ac\_scoringservice. It is an NIH-developed fatigue survey that includes 8 items that asks the participant about fatigue experience and impact over the past 7 days. Each item will be scored on a 5-point Likert scale (1=never/not at all to 5=almost always/very much). Raw scores (range: 8-40) will be converted into standardized T scores (range: 34.1-80.9), with higher scores indicating greater fatigue severity. A negative change from baseline indicates an improvement.
Time frame: At Week 32
Part 1a: Percentage of Participants With a Meaningful Within-person Change at Week 32 in the MFSAF TSS4
The MFSAF v4.0 is a questionnaire developed by the PRO Consortium's Myelofibrosis Working Group that focuses on the 7 core symptoms of myelofibrosis: fatigue, night sweats, pruritus, abdominal discomfort, pain under the ribs on the left side, early satiety, and bone pain. It includes 7 items on a 0 (absent) to 10 (worst imaginable) numeric rating scale. The MFSAF TSS4 is the sum of four items in the MFSAF (fatigue, itching \[pruritis\], night sweats, and abdominal discomfort). The weekly TSS4 will be calculated by averaging daily scores over a 7-day interval leading to Week 32 (inclusive).
Time frame: At Week 32
Part 1a: Percentage of Participants With a Meaningful Within-person Change at Week 32 in the MPN-SAF Problems With Concentration
MPN-SAF is a 10-item questionnaire measurement tool for symptoms of MPNs. Moderate or severe symptoms are defined as a baseline MPN-SAF problems with concentration ≥ 4. The descriptive analysis approach the distribution of the MPN-SAF problems with concentration at Baseline was categorized using the PGI-S. The response quartiles were used to establish the recommended cut-off points for the MPN-SAF Problems with Concentration corresponding to "none" or "mild" versus "moderate or "severe" categories on the PGI-S.
Time frame: At Week 32
Change From Baseline at Each Scheduled Assessment in Individual Symptom Score and the Total Score Based on MPN-SAF TSS 10
MPN-SAF is a 10-item questionnaire measurement tool for symptoms of MPNs. Moderate or severe symptoms are defined as a baseline MPN-SAF problems with concentration ≥ 4. The descriptive analysis approach the distribution of the MPN-SAF problems with concentration at Baseline was categorized using the PGI-S. The response quartiles were used to establish the recommended cut-off points for the MPN-SAF Problems with Concentration corresponding to "none" or "mild" versus "moderate or "severe" categories on the PGI-S.
Time frame: Baseline to end of study (up to approximately 5 years)
Change From Baseline in Patient Global Impression of Severity (PGI-S) at Each Scheduled Assessment
The PGI-S is a single question to assess the severity of PV symptoms over the last 24 hours prior to dosing. The participant will determine the severity of their PV symptoms on a 4-point scale ranging from "None" (0) to "Severe" (3). A higher score indicates worse symptoms. A negative change from baseline indicates an improvement.
Time frame: Baseline to end of study (up to approximately 5 years)
Percentage of Participants With at Least One Unit Improvement in the PGI-S From Baseline at Each Scheduled Assessment
The PGI-S is a single question to assess the severity of PV symptoms over the last 24 hours prior to dosing. The participant will determine the severity of their PV symptoms on a 4-point scale ranging from "None" (0) to "Severe" (3). A higher score indicates worse symptoms. A negative change from baseline indicates an improvement.
Time frame: Baseline to end of study (up to approximately 5 years)
Percentage of Participants With a Rating on the Patient Global Impression of Change (PGI-C) of Either "Much Better" or "a Little Better" at Each Scheduled Assessment
PGI-C is a simple, commonly used instrument to obtain a participant's overall assessment of the impact of treatment on the participant's quality of life. Participants will compare his/her condition from the start of the study on a 5-point scale ranging from "Much better" (1) to "Much worse" (5) at the time of the assessment.
Time frame: Baseline to end of study (up to approximately 5 years)
Mean PGI-C at Each Scheduled Assessment
PGI-C is a simple, commonly used instrument to obtain a participant's overall assessment of the impact of treatment on the participant's quality of life. Participants will compare his/her condition from the start of the study on a 5-point scale ranging from "Much better" (1) to "Much worse" (5) at the time of the assessment. A higher score indicates a worse condition.
Time frame: Baseline to end of study (up to approximately 5 years)
Change From Baseline at Each Scheduled Assessment in Individual Symptom Score and the MFSAF v4.0 Total Symptom Score-7 Items (TSS7)
The MFSAF version 4.0 (v4.0) TSS7 is a questionnaire developed by the Patient-Reported Outcome (PRO) Consortium's Myelofibrosis Working Group that focuses on the 7 core symptoms of myelofibrosis: fatigue, night sweats, pruritus, abdominal discomfort, pain under the ribs on the left side, early satiety, and bone pain. It includes 7 items on a 0 (absent) to 10 (worst imaginable) numeric rating scale. A higher score indicates worse symptoms. A negative change from baseline indicates an improvement.
Time frame: Baseline to end of study (up to approximately 5 years)
Change From Baseline in the Individual Domain Scores and the Total European Organization for Research and Treatment of Cancer Quality of Life Questionnaire (EORTC QLQ-C30) Score
The EORTC QLQ-C30 is a validated instrument to obtain a participant's overall assessment of the impact of treatment on the participant's quality of life. It consists of 5 functional scales (physical, role, cognitive, emotional, and social functioning), a global quality of life (QoL) scale, 3 symptom scales (fatigue, nausea and vomiting, and pain), and 6 single items (appetite loss, diarrhea, dyspnea, constipation, insomnia, financial impact). For the functional and the global QoL scales, a higher score indicates better health. For the symptom scales, a higher score indicates more symptom burden. The QLQ-C30 summary score is calculated as the mean of the combined 13 QLQ-C30 scale and item scores (excluding global QoL and financial impact), with a higher score indicating a better health related QoL. Raw scores are converted into scale scores ranging from 0 to 100.
Time frame: Baseline, Week 32
Median Time to First Hematocrit Equal to or Greater Than 45% After Randomization
Time frame: Baseline to end of study (up to approximately 5 years)
Median Time to Phlebotomy-eligible After Randomization
Phlebotomy eligibility was defined as either: 1) A confirmed HCT ≥ 45% that was at least 3% higher than the baseline HCT, where confirmation was defined as 2 consecutive HCT assessments that were ≥ 45% and at least 3% higher than the baseline HCT, or 2) HCT ≥ 48%.
Time frame: Baseline to end of study (up to approximately 5 years)
Percentage of Participants With at Least One Hematocrit Equal to or Greater Than 48%
Time frame: Baseline to end of study (up to approximately 5 years)
Percentage of Participants Who Maintain Absence of Phlebotomy Eligibility
Phlebotomy eligibility was defined as either: 1) A confirmed HCT ≥ 45% that was at least 3% higher than the baseline HCT, where confirmation was defined as 2 consecutive HCT assessments that were ≥ 45% and at least 3% higher than the baseline HCT, or 2) HCT ≥ 48%.
Time frame: Baseline to end of study (up to approximately 5 years)
Phlebotomy Annualized Rate
Time frame: Baseline to end of study (up to approximately 5 years)
Parts 1a + 1b: Percentage of Participants Originally Randomized to Rusfertide Achieving Absence of Phlebotomy Eligibility More Than 52 Weeks
Phlebotomy eligibility was defined as either: 1) A confirmed HCT ≥ 45% that was at least 3% higher than the baseline HCT, where confirmation was defined as 2 consecutive HCT assessments that were ≥ 45% and at least 3% higher than the baseline HCT, or 2) HCT ≥ 48%.
Time frame: Baseline to Week 52
Part 1b: Median Time to First Hematocrit Equal to or Greater Than 45%
Time frame: Week 32 to Week 52
Part 1b: Median Time to First Phlebotomy
Time frame: Week 32 to Week 52
Parts 1a + 1b: Percentage of Participants With All Hematocrit Values Less Than 45%
Time frame: Baseline to Week 52
Parts 1a + 1b: Percentage of Participants Randomized to Placebo Who Meet the Phlebotomy Eligibility in Part 1a and Part 1b, Separately
Phlebotomy eligibility was defined as either: 1) A confirmed HCT ≥ 45% that was at least 3% higher than the baseline HCT, where confirmation was defined as 2 consecutive HCT assessments that were ≥ 45% and at least 3% higher than the baseline HCT, or 2) HCT ≥ 48%.
Time frame: Baseline to Week 52
Percentage of Participants With Treatment-emergent Adverse Events (TEAEs)
Time frame: Baseline up to end of study (up to approximately 5 years)
A total of 293 participants participated in this study across 102 sites starting on 11 April 2022. This study is ongoing. Included here are the primary results.
| Milestone | Part 1a: Randomized, Double-Blind Period: Placebo | Part 1a: Randomized, Double-Blind Period: Rusfertide | Part 1b: Open-Label Treatment Period: Rusfertide | Part 2: Long Term Extension Period: Rusfertide |
|---|---|---|---|---|
| Started | 146 | 147 | 0 | 0 |
| Completed | 141 | 134 | 0 | 0 |
| Not completed | 5 | 13 | 0 | 0 |
| Withdrew: Adverse event | 4 | 8 | 0 | 0 |
| Withdrew: Disease progression | 1 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 0 | 3 | 0 | 0 |
| Withdrew: Randomized but not treated | 0 | 2 | 0 | 0 |
| Milestone | Part 1a: Randomized, Double-Blind Period: Placebo | Part 1a: Randomized, Double-Blind Period: Rusfertide | Part 1b: Open-Label Treatment Period: Rusfertide | Part 2: Long Term Extension Period: Rusfertide |
|---|---|---|---|---|
| Started | 0 | 0 | 274 | 0 |
| Completed | 0 | 0 | 267 | 0 |
| Not completed | 0 | 0 | 7 | 0 |
| Withdrew: Adverse event | 0 | 0 | 3 | 0 |
| Withdrew: Lack of efficacy | 0 | 0 | 2 | 0 |
| Withdrew: Reason not specified | 0 | 0 | 1 | 0 |
| Withdrew: Withdrawal by subject | 0 | 0 | 1 | 0 |
| Milestone | Part 1a: Randomized, Double-Blind Period: Placebo | Part 1a: Randomized, Double-Blind Period: Rusfertide | Part 1b: Open-Label Treatment Period: Rusfertide | Part 2: Long Term Extension Period: Rusfertide |
|---|---|---|---|---|
| Started | 0 | 0 | 0 | 267 |
| Completed | 0 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 0 | 267 |
| Withdrew: Study ongoing | 0 | 0 | 0 | 254 |
| Withdrew: Adverse event | 0 | 0 | 0 | 4 |
| Withdrew: Disease progression | 0 | 0 | 0 | 2 |
| Withdrew: Lack of efficacy | 0 | 0 | 0 | 2 |
| Withdrew: Withdrawal by subject | 0 | 0 | 0 | 4 |
| Withdrew: Reason not specified | 0 | 0 | 0 | 1 |
Response was defined as absence of phlebotomy eligibility. Phlebotomy eligibility was defined as either: 1) A confirmed hematocrit (HCT) greater than or equal to (≥) 45% that was at least 3% higher than the baseline HCT, where confirmation was defined as 2 consecutive HCT assessments that were ≥ 45% and at least 3% higher than the baseline HCT, or 2) HCT ≥ 48%.
| percentage of participants | Part 1a: Randomized, Double-Blind Period: Placebo | Part 1a: Randomized, Double-Blind Period: Rusfertide |
|---|---|---|
| Part 1a: Percentage of Participants Who Achieved Response | 32.9 | 76.9 |
Results for this outcome have not been posted.
Results for this outcome have not been posted.
The PROMIS Fatigue SF 8a T-score will be obtained via the item-response theory (IRT) response-pattern scoring approach using the PROMIS Scoring Service available at https://www.assessmentcenter.net/ac\_scoringservice. It is an National Institutes of Health (NIH)-developed fatigue survey of 8 items that asks the participant about fatigue experience and impact over the past 7 days. Each item will be scored on a 5-point Likert scale (1=never/not at all to 5=almost always/very much). Raw scores (range: 8-40) will be converted into standardized T scores (range: 34.1-80.9), with higher scores indicating greater fatigue severity. A negative change from baseline indicates an improvement.
Results for this outcome have not been posted.
The MFSAF version 4.0 (v4.0) TSS7 is a questionnaire developed by the Patient-Reported Outcome (PRO) Consortium's Myelofibrosis Working Group that focuses on the 7 core symptoms of myelofibrosis: fatigue, night sweats, pruritus, abdominal discomfort, pain under the ribs on the left side, early satiety, and bone pain. It includes 7 items on a 0 (absent) to 10 (worst imaginable) numeric rating scale. A higher score indicates worse symptoms. A negative change from baseline indicates an improvement.
Results for this outcome have not been posted.
The PROMIS Fatigue SF 8a T-score will be obtained via the IRT response-pattern scoring approach using the PROMIS Scoring Service available at https://www.assessmentcenter.net/ac\_scoringservice. It is a National Institutes of Health (NIH)-developed fatigue survey of 8 items that asks the participant about fatigue experience and impact over the past 7 days. Each item will be scored on a 5-point Likert scale (1=never/not at all to 5=almost always/very much). Raw scores (range: 8-40) will be converted into standardized T scores (range: 34.1-80.9), with higher scores indicating greater fatigue severity. Moderate or severe symptoms are defined as a baseline PROMIS Fatigue SF 8aT-score \>/= 58.8. A negative change from baseline indicates an improvement.
Results for this outcome have not been posted.
The MFSAF v4.0 is a questionnaire developed by the PRO Consortium's Myelofibrosis Working Group that focused on the 7 core symptoms of myelofibrosis: fatigue, night sweats, pruritus, abdominal discomfort, pain under the ribs on the left side, early satiety, and bone pain. Items are scored on a 0 (absent) to 10 (worst imaginable) numeric rating scale. The MFSAF TSS4 is the sum of four items in the MFSAF (fatigue, itching \[pruritis\], night sweats, and abdominal discomfort). The weekly TSS4 will be calculated by averaging daily scores over a 7-day interval leading to Week 32 (inclusive). Moderate or severe symptoms are defined as a baseline MFSAF TSS4 \>/=9.1. A higher score indicates worse symptoms. A negative change from baseline indicates an improvement.
Results for this outcome have not been posted.
MPN-SAF is a 10-item questionnaire measurement tool for symptoms of MPNs. Moderate or severe symptoms are defined as baseline MPN-SAF problems with concentration ≥4. The descriptive analysis approach the distribution of the MPN-SAF problems with concentration at Baseline will be categorized using the Patient Global Impression of Severity (PGI-S). The response quartiles will be used to establish the recommended cut-off points for the MPN-SAF Problems with Concentration corresponding to "none" or "mild" versus "moderate or "severe" categories on the PGI-S.
Results for this outcome have not been posted.
The PROMIS Fatigue SF 8a T-score will be obtained via the IRT response-pattern scoring approach using the PROMIS Scoring Service available at https://www.assessmentcenter.net/ac\_scoringservice. It is an NIH-developed fatigue survey of 8 items that asks the participant about fatigue experience and impact over the past 7 days. Each item will be scored on a 5-point Likert scale (1=never/not at all to 5=almost always/very much). Raw scores (range: 8-40) will be converted into standardized T scores (range: 34.1-80.9), with higher scores indicating greater fatigue severity. Moderate or severe symptoms are defined as a baseline PROMIS Fatigue SF 8aT-score \>/= 58.8.
Results for this outcome have not been posted.
The MFSAF v4.0 is a questionnaire developed by the PRO Consortium's Myelofibrosis Working Group that focuses on the 7 core symptoms of myelofibrosis: fatigue, night sweats, pruritus, abdominal discomfort, pain under the ribs on the left side, early satiety, and bone pain. It included 7 items on a 0 (absent) to 10 (worst imaginable) numeric rating scale. The MFSAF TSS4 is the sum of four items in the MFSAF (fatigue, itching \[pruritis\], night sweats, and abdominal discomfort). The weekly TSS4 will be calculated by averaging daily scores over a 7-day interval leading to Week 32 (inclusive). Moderate or severe symptoms are defined as a baseline MFSAF TSS4 \>/=9.1.
Results for this outcome have not been posted.
MPN-SAF is a 10-item questionnaire measurement tool for symptoms of MPNs. Moderate or severe symptoms are defined as baseline MPN-SAF problems with concentration ≥4. The descriptive analysis approach the distribution of the MPN-SAF problems with concentration at Baseline was categorized using the PGI-S. The response quartiles were used to establish the recommended cut-off points for the MPN-SAF Problems with Concentration corresponding to "none" or "mild" versus "moderate or "severe" categories on the PGI-S.
Results for this outcome have not been posted.
The PROMIS Fatigue SF 8a T-score will be obtained via the IRT response-pattern scoring approach using the PROMIS Scoring Service available at https://www.assessmentcenter.net/ac\_scoringservice. It is an NIH-developed fatigue survey that includes 8 items that asks the participant about fatigue experience and impact over the past 7 days. Each item will be scored on a 5-point Likert scale (1=never/not at all to 5=almost always/very much). Raw scores (range: 8-40) will be converted into standardized T scores (range: 34.1-80.9), with higher scores indicating greater fatigue severity.
Results for this outcome have not been posted.
The PROMIS Fatigue SF 8a T-score was obtained via the IRT response-pattern scoring approach using the PROMIS Scoring Service available at https://www.assessmentcenter.net/ac\_scoringservice. It is a National Institutes of Health (NIH)-developed fatigue survey of 8 items that asks the participant about fatigue experience and impact over the past 7 days. Each item will be scored on a 5-point Likert scale (1=never/not at all to 5=almost always/very much). Raw scores (range: 8-40) will be converted into standardized T scores (range: 34.1-80.9), with higher scores indicating greater fatigue severity. Moderate or severe symptoms are defined as a baseline PROMIS Fatigue SF 8aT-score \>/= 58.8. A negative change from baseline indicates an improvement.
Results for this outcome have not been posted.
The MFSAF v4.0 is a questionnaire developed by the PRO Consortium's Myelofibrosis Working Group that focuses on the 7 core symptoms of myelofibrosis: fatigue, night sweats, pruritus, abdominal discomfort, pain under the ribs on the left side, early satiety, and bone pain. It includes 7 items on a 0 (absent) to 10 (worst imaginable) numeric rating scale. A higher score indicates worse symptoms.
Results for this outcome have not been posted.
The MFSAF v4.0 is a questionnaire developed by the PRO Consortium's Myelofibrosis Working Group that focused on the 7 core symptoms of myelofibrosis: fatigue, night sweats, pruritus, abdominal discomfort, pain under the ribs on the left side, early satiety, and bone pain. Items are scored on a 0 (absent) to 10 (worst imaginable) numeric rating scale. The MFSAF TSS4 is the sum of four items in the MFSAF (fatigue, itching \[pruritis\], night sweats, and abdominal discomfort). The weekly TSS4 will be calculated by averaging daily scores over a 7-day interval leading to Week 32 (inclusive). Moderate or severe symptoms are defined as a baseline MFSAF TSS4 \>/=9.1. A higher score indicates worse symptoms. A negative change from baseline indicates an improvement.
Results for this outcome have not been posted.
The PROMIS Fatigue SF 8a T-score will be obtained via the IRT response-pattern scoring approach using the PROMIS Scoring Service available at https://www.assessmentcenter.net/ac\_scoringservice. It is an NIH-developed fatigue survey that includes 8 items that asks the participant about fatigue experience and impact over the past 7 days. Each item will be scored on a 5-point Likert scale (1=never/not at all to 5=almost always/very much). Raw scores (range: 8-40) will be converted into standardized T scores (range: 34.1-80.9), with higher scores indicating greater fatigue severity. A negative change from baseline indicates an improvement.
Results for this outcome have not been posted.
The MFSAF v4.0 is a questionnaire developed by the PRO Consortium's Myelofibrosis Working Group that focuses on the 7 core symptoms of myelofibrosis: fatigue, night sweats, pruritus, abdominal discomfort, pain under the ribs on the left side, early satiety, and bone pain. It includes 7 items on a 0 (absent) to 10 (worst imaginable) numeric rating scale. The MFSAF TSS4 is the sum of four items in the MFSAF (fatigue, itching \[pruritis\], night sweats, and abdominal discomfort). The weekly TSS4 will be calculated by averaging daily scores over a 7-day interval leading to Week 32 (inclusive).
Results for this outcome have not been posted.
MPN-SAF is a 10-item questionnaire measurement tool for symptoms of MPNs. Moderate or severe symptoms are defined as a baseline MPN-SAF problems with concentration ≥ 4. The descriptive analysis approach the distribution of the MPN-SAF problems with concentration at Baseline was categorized using the PGI-S. The response quartiles were used to establish the recommended cut-off points for the MPN-SAF Problems with Concentration corresponding to "none" or "mild" versus "moderate or "severe" categories on the PGI-S.
Results for this outcome have not been posted.
MPN-SAF is a 10-item questionnaire measurement tool for symptoms of MPNs. Moderate or severe symptoms are defined as a baseline MPN-SAF problems with concentration ≥ 4. The descriptive analysis approach the distribution of the MPN-SAF problems with concentration at Baseline was categorized using the PGI-S. The response quartiles were used to establish the recommended cut-off points for the MPN-SAF Problems with Concentration corresponding to "none" or "mild" versus "moderate or "severe" categories on the PGI-S.
Results for this outcome have not been posted.
The PGI-S is a single question to assess the severity of PV symptoms over the last 24 hours prior to dosing. The participant will determine the severity of their PV symptoms on a 4-point scale ranging from "None" (0) to "Severe" (3). A higher score indicates worse symptoms. A negative change from baseline indicates an improvement.
Results for this outcome have not been posted.
The PGI-S is a single question to assess the severity of PV symptoms over the last 24 hours prior to dosing. The participant will determine the severity of their PV symptoms on a 4-point scale ranging from "None" (0) to "Severe" (3). A higher score indicates worse symptoms. A negative change from baseline indicates an improvement.
Results for this outcome have not been posted.
PGI-C is a simple, commonly used instrument to obtain a participant's overall assessment of the impact of treatment on the participant's quality of life. Participants will compare his/her condition from the start of the study on a 5-point scale ranging from "Much better" (1) to "Much worse" (5) at the time of the assessment.
Results for this outcome have not been posted.
PGI-C is a simple, commonly used instrument to obtain a participant's overall assessment of the impact of treatment on the participant's quality of life. Participants will compare his/her condition from the start of the study on a 5-point scale ranging from "Much better" (1) to "Much worse" (5) at the time of the assessment. A higher score indicates a worse condition.
Results for this outcome have not been posted.
The MFSAF version 4.0 (v4.0) TSS7 is a questionnaire developed by the Patient-Reported Outcome (PRO) Consortium's Myelofibrosis Working Group that focuses on the 7 core symptoms of myelofibrosis: fatigue, night sweats, pruritus, abdominal discomfort, pain under the ribs on the left side, early satiety, and bone pain. It includes 7 items on a 0 (absent) to 10 (worst imaginable) numeric rating scale. A higher score indicates worse symptoms. A negative change from baseline indicates an improvement.
Results for this outcome have not been posted.
The EORTC QLQ-C30 is a validated instrument to obtain a participant's overall assessment of the impact of treatment on the participant's quality of life. It consists of 5 functional scales (physical, role, cognitive, emotional, and social functioning), a global quality of life (QoL) scale, 3 symptom scales (fatigue, nausea and vomiting, and pain), and 6 single items (appetite loss, diarrhea, dyspnea, constipation, insomnia, financial impact). For the functional and the global QoL scales, a higher score indicates better health. For the symptom scales, a higher score indicates more symptom burden. The QLQ-C30 summary score is calculated as the mean of the combined 13 QLQ-C30 scale and item scores (excluding global QoL and financial impact), with a higher score indicating a better health related QoL. Raw scores are converted into scale scores ranging from 0 to 100.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Phlebotomy eligibility was defined as either: 1) A confirmed HCT ≥ 45% that was at least 3% higher than the baseline HCT, where confirmation was defined as 2 consecutive HCT assessments that were ≥ 45% and at least 3% higher than the baseline HCT, or 2) HCT ≥ 48%.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Phlebotomy eligibility was defined as either: 1) A confirmed HCT ≥ 45% that was at least 3% higher than the baseline HCT, where confirmation was defined as 2 consecutive HCT assessments that were ≥ 45% and at least 3% higher than the baseline HCT, or 2) HCT ≥ 48%.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Phlebotomy eligibility was defined as either: 1) A confirmed HCT ≥ 45% that was at least 3% higher than the baseline HCT, where confirmation was defined as 2 consecutive HCT assessments that were ≥ 45% and at least 3% higher than the baseline HCT, or 2) HCT ≥ 48%.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Phlebotomy eligibility was defined as either: 1) A confirmed HCT ≥ 45% that was at least 3% higher than the baseline HCT, where confirmation was defined as 2 consecutive HCT assessments that were ≥ 45% and at least 3% higher than the baseline HCT, or 2) HCT ≥ 48%.
Results for this outcome have not been posted.
Results for this outcome have not been posted.
Collected over Part 1a: From Baseline up to Week 32; Part 1b: From Week 32 to Week 52, Part 2: From Week 52 up to data cut-off date 21 February 2025 (approximately 2 years); Part 2 is ongoing. Part 3 has not started as of data cutoff date 21 February 2025. Adverse events are still being collected and will be updated one year after study completion date.. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Part 1a: Randomized, Placebo-Controlled Period: Placebo | 0/146 (0%) | 7/146 (4.8%) | 101/146 (69.2%) |
| Part 1a: Randomized, Placebo-Controlled Period: Rusfertide | 0/147 (0%) | 5/145 (3.4%) | 115/145 (79.3%) |
| Part 1b: Open-Label Treatment Phase | 0/274 (0%) | 7/274 (2.6%) | 139/274 (50.7%) |
| Part 2: Long Term Extension | 0/267 (0%) | 10/266 (3.8%) | 104/266 (39.1%) |
| Event | Part 1a: Randomized, Placebo-Controlled Period: Placebo | Part 1a: Randomized, Placebo-Controlled Period: Rusfertide | Part 1b: Open-Label Treatment Phase | Part 2: Long Term Extension |
|---|---|---|---|---|
| Acute myocardial infarctionCardiac disorders | 0/146 | 1/145 | 0/274 | 1/266 |
| Blood glucose increasedInvestigations | 0/146 | 1/145 | 0/274 | 0/266 |
| Diabetic ketoacidosisMetabolism and nutrition disorders | 0/146 | 1/145 | 0/274 | 0/266 |
| HaematomaVascular disorders | 0/146 | 1/145 | 0/274 | 0/266 |
| HaematuriaRenal and urinary disorders | 0/146 | 1/145 | 1/274 | 0/266 |
| Bullous erysipelasInfections and infestations | 1/146 | 0/145 | 0/274 | 0/266 |
| Colorectal cancerNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/146 | 0/145 | 0/274 | 0/266 |
| DiarrhoeaGastrointestinal disorders | 1/146 | 0/145 | 0/274 | 0/266 |
| Drug hypersensitivityImmune system disorders | 1/146 | 0/145 | 0/274 | 0/266 |
| HeadacheNervous system disorders | 1/146 | 0/145 | 0/274 | 0/266 |
| Event | Part 1a: Randomized, Placebo-Controlled Period: Placebo | Part 1a: Randomized, Placebo-Controlled Period: Rusfertide | Part 1b: Open-Label Treatment Phase | Part 2: Long Term Extension |
|---|---|---|---|---|
| Injection site erythemaGeneral disorders | 11/146 | 45/145 | 31/274 | 12/266 |
| Injection site pruritusGeneral disorders | 4/146 | 26/145 | 19/274 | 5/266 |
| FatigueGeneral disorders | 23/146 | 22/145 | 26/274 | 14/266 |
| Injection site painGeneral disorders | 23/146 | 20/145 | 18/274 | 9/266 |
| AnaemiaBlood and lymphatic system disorders | 6/146 | 22/145 | 29/274 | 32/266 |
| COVID-19Infections and infestations | 16/146 | 14/145 | 6/274 | 4/266 |
| HeadacheNervous system disorders | 16/146 | 15/145 | 8/274 | 10/266 |
| PruritusSkin and subcutaneous tissue disorders | 15/146 | 15/145 | 8/274 | 9/266 |
| DiarrhoeaGastrointestinal disorders | 9/146 | 12/145 | 8/274 | 14/266 |
| DizzinessNervous system disorders | 9/146 | 12/145 | 4/274 | 11/266 |
The Intent-to-Treat (ITT) Set comprised all randomized participants according to the treatment assigned at randomization.
| Age, Continuous(years) | Part 1a: Randomized, Double-Blind Period: Placebo | Part 1a: Randomized, Double-Blind Period: Rusfertide | Total |
|---|---|---|---|
| Mean | 57.3 ± 10.45 | 56.7 ± 12.20 | 57 ± 11.35 |
| Sex: Female, Male(Participants) | Part 1a: Randomized, Double-Blind Period: Placebo | Part 1a: Randomized, Double-Blind Period: Rusfertide | Total |
|---|---|---|---|
| Female | 38 | 41 | 79 |
| Male | 108 | 106 | 214 |
| Ethnicity (NIH/OMB)(Participants) | Part 1a: Randomized, Double-Blind Period: Placebo | Part 1a: Randomized, Double-Blind Period: Rusfertide | Total |
|---|---|---|---|
| Hispanic or Latino | 6 | 8 | 14 |
| Not Hispanic or Latino | 132 | 134 | 266 |
| Unknown or Not Reported | 8 | 5 | 13 |
| Race/Ethnicity, Customized(Participants) | Part 1a: Randomized, Double-Blind Period: Placebo | Part 1a: Randomized, Double-Blind Period: Rusfertide | Total |
|---|---|---|---|
| White | 133 | 129 | 262 |
| Black or African American | 1 | 1 | 2 |
| Asian | 4 | 5 | 9 |
| American Indian or Alaska Native | 2 | 0 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Multiple | 0 | 0 | 0 |
| Not Reported | 4 | 6 | 10 |
| Other | 1 | 6 | 7 |
| Unknown | 1 | 0 | 1 |
Showing the first 100 of 184 sites across 20 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.
Supporting information: Study protocol, Statistical analysis plan, Informed consent form, Clinical study report
Access criteria: IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement
Data sharing details ↗ · vivli.org
Ran from Apr 2022 to primary completion in Feb 2025, 34 months.
Results were first posted in Oct 2026, 1 year 7 months after primary completion.
Completion moved once since we started tracking on Sep 25, 2026: Jun 2027 → Aug 2028, on Oct 19, 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
…and 4 more changes, on the record history on ClinicalTrials.gov ↗
…and 4 more changes, on the record history on ClinicalTrials.gov ↗
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is active, not recruiting, as verified in Sep 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Rusfertide
Protagonist Therapeutics, Inc.